Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TORL-2-307-ADC
- Development stage
- Phase 1
- Lead developer
- TORL BioTherapeutics
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TORL-2-307-ADC is an investigational antibody-drug conjugate (ADC) developed by TORL Biotherapeutics for the treatment of advanced cancers, including adenocarcinoma, gastrointestinal cancer, pancreatic cancer, and esophageal cancer. The drug consists of a monoclonal antibody targeting claudin 18.2 (CLDN18.2), a tumor-associated antigen overexpressed in certain cancers, conjugated to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding to CLDN18.2-expressing tumor cells and internalization, MMAE is released intracellularly to inhibit tubulin polymerization and induce cell death in targeted cancer cells[1][3][6][8]. The drug is currently being evaluated in phase 1 clinical trials.
- Other names
- TORL-2-307ADCTORL2-307ADCTORL 2-307ADCTORL2307ADC-001TORL-2307ADC-001TORL 2307ADC-001
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on TORL-2-307-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TORL-2-307-ADC.